Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025 [Yahoo! Finance]
Corvus Pharmaceuticals, Inc. (CRVS)
Last corvus pharmaceuticals, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corvuspharma.com
Company Research
Source: Yahoo! Finance
Company to discuss data on its first quarter 2025 business update conference call and webcast scheduled for 4:30 pm ET / 1:30 pm PT on May 8, 2025 SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis will be presented in an oral session and poster at the Society for Investigative Dermatology 2025 Annual Meeting, which is taking place May 7-10, 2025 in San Diego, CA. Presentation details are as follows: Title: Selective Soquelitinib, a selective ITK inhibitor demonstrates activity in atopic dermatitis phase 1 clinical trial by a novel mechanism of action Abstract #: Presenter: Albert S. Chiou, M.D., MBA, Clinical Associate Professor, Dermatology and Director of Clinical Research in the D
Show less
Read more
Impact Snapshot
Event Time:
CRVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRVS alerts
High impacting Corvus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRVS
News
- Corvus Pharmaceuticals (NASDAQ:CRVS) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.MarketBeat
- Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma TrialGlobeNewswire
- Corvus Pharmaceuticals: Moving Slowly Forward [Seeking Alpha]Seeking Alpha
- Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial ResultsGlobeNewswire
CRVS
Earnings
- 11/4/25 - Beat
CRVS
Sec Filings
- 12/8/25 - Form 4
- 12/8/25 - Form 4
- 12/8/25 - Form 4
- CRVS's page on the SEC website